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Abstract 
Background: To study the frequency and 
specificity of various red cell alloantibodies in multi- 
transfused patients of beta thalassaemia major. 
Methods: In this comparative study two hundred 
diagnosed cases of Beta Thalassemia Major , of all 
ages and both genders, who received at least ten 
blood transfusions,  were included .Patients with 
known alloantibodies, or with known autoimmune 
diseases,patients with known renal or liver disorders 
and with viral infections were excluded.Five ml 
venous blood was taken in a clear glass tube. Sera 
were separated and blood grouping and direct and 
indirect anti-globulin tests were performed on all 
samples. Samples positive for indirect anti-globulin 
test were stored in aliquots at -20 °C, till the tests 
were performed in batches. After thawing, antibody 
screening and antibody identification tests were 
performed in batches of ten on all indirect anti-
globulin test (IAT) positive samples employing 11 
cell panel of DIA-MED using standardized blood 
bank methods. All the results were recorded.The 
alloantibodies detected and their specificity was 
determined. 
Results: Out of 200 patients  six patients (3%) were 
diagnosed to have alloantibodies which belonged to 
Rh system i.e. Anti-E and Anti-D. 
Conclusion:Rate of alloimmunization is low in our 
setup in multi- transfused patients of beta 
thalassaemia major. The most common alloantibody 
found in our patients is Anti-E.  
Key Words:Beta Thalassaemia Major,Transfusion 
dependent anaemias, Red cell  alloantibodies. 
 
Introduction 
Thalassaemias are heterogeneous group of genetic 
disorders of hemoglobin synthesis  which result from a 
reduced rate of production or absence of one or more 
of the globin chains of hemoglobin.1Beta thalassaemia 
major is a severe transfusion dependent, inherited 
anemia in which there is a profound defect of beta 
chain production. Excess alpha chains precipitates and 
accumulate in the red cell precursors in the bone 
marrow resulting in ineffective erythropoiesis2. 
There are many mutations which causes thalassaemia 
and related disorders.3 These mutations can affect 
every step in the pathway of globin gene expression, 
transcription, processing of the mRNA precursor, 
translation of mature mRNA, and preservation of post 
translational integrity of the Beta chain. More than 200 
mutations in beta chain have been described.4 
 The curative standard treatment for Beta 
Thalassaemia Major is stem cell transplant which is 
highly  specialized  and expensive procedure thus not 
affordable by most of the patients. The main and 
commonly practicing treatment modality for 
homozygous  Beta-Thalassaemia remains regular 
blood transfusion along with iron chelation to remove 
the antecedent transfusional iron overload.5  
 Alloimmunization of red blood cells in multiple 
transfused patients of beta thalassaemia major 
complicates the transfusion therapy in these patients.6 
Alloimmunization of red blood cells is dependent on 
genetic and acquired patient related factors, number of 
transfusion received and immunogenicity of the 
antigen.7 Heterogeniety of population, lack of better 
matched donor for thalassaemic patients and use of 
post storage blood may contribute to high 
alloimmunization rate.8 
RBC alloimmunization has a significant negative 
impact on laboratory and in institutional resources, 
associated with a need for increased laboratory testing 
difficulties in identification and procurement of 
compatible blood units for transfusion, and with the 
evaluation and management of transfusion 
reactions.9Antibody screening tests are not routinely 
performed before transfusion in patients of 
thalassemia. As a result undetected antibodies at the 
time of new transfusion can cause hemolytic 
transfusion reactions.7,10 
Patients and Methods 
This descriptive study was carried out at Thalassaemia 
treatment centre, Holy Family Hospital Rawalpindi. 
Two hundred diagnosed cases of Beta Thalassemia 
Major , of all ages and both genders, who received at 
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least ten blood transfusions,  were included .Patients 
with known alloantibodies, or with known 
autoimmune diseases,patients with known renal or 
liver disorders and with viral infections  were 
excluded .Total number of transfusions received, 
transfusion interval and annual transfusion 
requirement were noted. Five ml venous blood was 
taken in a clear glass tube. Sera were separated and 
blood grouping and direct and indirect anti-globulin 
tests were performed on all samples. Samples positive 
for indirect anti-globulin test were stored in aliquots at 
-20 °C, till the tests were performed in batches. After 
thawing, antibody screening and antibody 
identification tests were performed in batches of ten on 
all indirect anti-globulin test (IAT) positive samples 
employing 11 cell panel of DIA-MED using 
standardized blood bank methods. All the results were 
recorded.The alloantibodies detected and their 
specificity was determined. 
 
Results 
Out of 200 patients of Beta-Thalassaemia Major 107 
(53.5%) were females and 93 (46.5%) were males . The 
age range  was from 2 years to 22 years with the mean 
age of 8.1 year. Maximum number of patients in this 
study belonged to 6-10 years of age Haemoglobin 
concentration ranged from 4.3 to 10.2 gm/dl with a 
mean concentration of 7.0 gm/ dl.  In total of 200 cases 
studied, all IAT positive cases were subjected to 
alloantibody screening and identification test . Red cell 
alloantibodies were detected in 6 (3%) patients (Table 
1). Anti- E was detected in 4 patients and Anti-D was 
present in2patients.( Table  2) 
 
Table 1: Age and sex distribution of alloantibodies 
Age No. of 
Patients 
Alloanti
bodies 
Males Femal
es 
Upto 5 
years 
42 None None None 
5-10 years 119 4 1 3 
10-15 years 31 2 1 1 
15-20 years 6 None None None 
>20 years 2 None None None 
 
Table 2: Type and Specificity of  
alloantibody detected 
type of antibody 
detected 
frequency of antibody 
detected 
Anti E 2% 
Anti D 1% 
Discussion 
According to present study, the frequency of red cell 
alloimmunization in thalassaemic patients receiving 
multiple blood transfusions in our set up is low i-e, 
only 3%.  Our results are in agreement with a study 
conducted by Bhatti F, etal ,at AFIT Rawalpindi.They 
reported  RBC alloimmunization  as 4.97% in 161 
patients which mainly belonged to Rh system and Kell 
system.10, 13  Our data contrast with a study conducted 
by Hassan K  et al, which showed higher rate of 
alloimmunization in patients of Beta thalassaemia 
major. Alloantibody was detected in 22.7% patients 
out of total 75 patients, and the most frequent 
alloantibody was found to be Anti-Kpa.12  A study at 
Aga Khan University Karachi by Bilwani F, et al, 
revealed a rate of alloimmunization of 9.2% in 97 
patients of thalassaemia major. Anti- k was the 
commonest followed by non-specific and anti-D. 11 In 
southern Iran and Shiraz 711 thalassaemic patients 
were studied by Karimi M, et al and in these patients 
5.3% were found to have alloantibodies .The most 
common alloantibodies were Anti –kell>Anti-Rh (D) 
>Anti-Rh (E).14 Wang LY, et al, in Taiwan revealed that 
of the 30 thalassaemic patients included in the study 
11 (37%) were found to have clinically significant 
alloantibodies, and most common antibody detected 
was Anti-E.6 In a study carried out in Saudia Arabia 
the development of alloantibodies were determined in 
68 multi-transfused patients and the overall frequency 
of alloantibody formation in our patients is 22.06%.15 
However in another study carried out in India  the 
overall incidence of RBC alloimmunization in 
transfused patients was 3.4% with anti-c being the 
most common specificity (38.8%), followed by anti-E 
(22.2%), anti-M (11.1%), anti-Le(a) (11.1%), anti-D 
(5.6%), anti-Jk(a) (5.6%) and anti-Le(b) (5.6%).16 
   If prevalent transfusion practices continue the 
problem of alloimmunization can be significantly 
increased.12Alloantibodies against red blood cells 
should not be overlooked in patients of Thalassaemia 
receiving multiple blood transfusions.11Ideally 
genotyping and cross matching of red blood cells of 
major and minor blood groups should be done in 
patients receiving multiple blood transfusions.9 
 
Conclusion 
1.Rate of red blood cell alloimmunization in multiply 
transfused patients of Beta-Thalassaemia major is low 
in our setup. The commonest alloantibody found in 
thalassaemic patients in our setup is Anti-E.  
2.The alloantibodies screening in transfusion 
dependent thalassaemics is imperative in cases with 
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difficulties in cross matching, having haemolytic 
transfusion reactions and in those who failed to 
maintain a desirable haemoglobin level. 
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